News & Events
ArcherDX’s Companion Diagnostic Test for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration
ArcherDX’s Companion Diagnostic Test for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration January 8, 2019 BOULDER, […]
Merck KGaA, Darmstadt, Germany Selects ArcherDX, Inc. for Strategic Global Companion Diagnostic Test Development Collaboration
Merck KGaA, Darmstadt, Germany Selects ArcherDX, Inc. for Strategic Global Companion Diagnostic Test Development Collaboration October 3, 2018 BOULDER, CO-ArcherDX, a molecular technology company dedicated […]
Washington University, ArcherDX, Inc. partner for MRD in pediatric AML sequencing study
Washington University, ArcherDX, Inc. partner for MRD in pediatric AML sequencing study April 12, 2018 BOULDER, CO-Washington University in St. Louis and ArcherDX, Inc. will […]
ArcherDX, Inc. and Ambry Genetics to provide immune repertoire and CAR-T- related sequencing services
ArcherDX, Inc. and Ambry Genetics to provide immune repertoire and CAR-T- related sequencing services Partnership accelerates the development of promising new immunotherapies March 26, 2018 […]
ArcherDX, Inc. Closes $35 Million Series A Financing
ArcherDX, Inc. Closes $35 Million Series A Financing March 20, 2018 BOULDER, CO—ArcherDX, Inc., the leader in NGS-based gene fusion detection tests, announced today that […]